Efficacy and safety of weekly nab-paclitaxel (nab-P) plus gemcitabine (Gem) in Chinese patients (Pts) with metastatic adenocarcinoma of the pancreas (MPC): A phase II study

被引：0
|
作者：
Yu, X. [1 ]
Shen, L. [2 ]
Hao, J. [3 ]
Wang, L. [4 ]
Pan, H. [5 ]
Han, G. [6 ]
Xu, J. [7 ]
Zhang, Y. [8 ]
Yang, S. [9 ]
Ying, J. [10 ]
Li, M. [11 ]
Begic, D. [12 ]
Lu, B. [12 ]
Xu, R. [13 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Dept Pancreat & Hepatobiliary Surg, Shanghai 200433, Peoples R China
[2] Peking Univ, Canc Hosp, Beijing Canc Hosp, Oncol, Beijing 100871, Peoples R China
[3] Tianjin Med Univ Canc Inst & Hosp, Oncol, Tianjin, Peoples R China
[4] 1st Shanghai Peoples Hosp, Oncol, Shanghai, Peoples R China
[5] Zhejiang Univ, Sir Run Run Shaw Hosp, Oncol, Hangzhou 310003, Zhejiang, Peoples R China
[6] 4th Mil Med Univ, Xijing Hosp, Oncol, Xian, Peoples R China
[7] 307th Hosp PLA AMMS China, Oncol, Beijing, Peoples R China
[8] 1st Hosp Harbin Inst Hematol, Oncol, Harbin, Peoples R China
[9] Henan Prov Anticanc Hosp, Oncol, Zhengzhou, Peoples R China
[10] Zhejiang Canc Hosp, Oncol, Hangzhou, Zhejiang, Peoples R China
[11] Celgene, Biostat, Summit, NJ USA
[12] Celgene, CR&D, Summit, NJ USA
[13] Sun Yat Sen Univ, Affiliated Hosp 1, Oncol, Guangzhou 510275, Guangdong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
223P
引用
收藏
页码：66 / 67
页数：2
相关论文
共 50 条
  • [1] A phase II study of Chinese patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) for metastatic pancreatic cancer (MPC)
    Shen, Lin
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jian-Ming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian D.
    Xu, Ruihua
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [2] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Ruihua Xu
    Xianjun Yu
    Jihui Hao
    Liwei Wang
    Hongming Pan
    Guohong Han
    Jianming Xu
    Yanqiao Zhang
    Shujun Yang
    Jia Chen
    Jieer Ying
    Guanghai Dai
    Mingyu Li
    Damir Begic
    Brian Lu
    Lin Shen
    BMC Cancer, 17
  • [3] Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: a phase II study
    Xu, Ruihua
    Yu, Xianjun
    Hao, Jihui
    Wang, Liwei
    Pan, Hongming
    Han, Guohong
    Xu, Jianming
    Zhang, Yanqiao
    Yang, Shujun
    Chen, Jia
    Ying, Jieer
    Dai, Guanghai
    Li, Mingyu
    Begic, Damir
    Lu, Brian
    Shen, Lin
    BMC CANCER, 2017, 17
  • [4] A PHASE I/II TRIAL OF WEEKLY NAB-PACLITAXEL (nab-P) plus GEMCITABINE(G) WITH METASTATIC PANCREATIC CANCER(MPC)
    Ikeda, Masafumi
    Ueno, Hideki
    Ueno, Makoto
    Mizuno, Nobumasa
    Ioka, Tatsuya
    Omuro, Yasushi
    Nakajima, Takako
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2014, 25
  • [5] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [6] Efficacy and safety of nab-Paclitaxel (nab-P) plus gemcitabine (Gem) vs gem alone in patients (Pts) with metastatic pancreatic cancer (MPC) treated to progressive disease (PD) in the phase III MPACT trial
    Vogel, A.
    Penenberg, D.
    McGovern, D.
    Romano, A.
    Michael, S.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S455 - S455
  • [7] Nomogram for predicting overall survival (OS) in patients (pts) treated with nab-paclitaxel (nab-P) plus gemcitabine (Gem) or Gem alone for metastatic pancreatic cancer (MPC).
    Goldstein, David
    Von Hoff, Daniel D.
    Chiorean, E. Gabriela
    Reni, Michele
    Tabernero, Josep
    Ramanathan, Ramesh K.
    Aly, Abdalla
    Botteman, Marc
    Wilkersen, Julia
    Margunato-Debay, Sandra
    Lu, Brian
    Louis, Chrystal Ursula
    Renschler, Markus Frederic
    McGovern, Desmond Micahel Thomas
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer
    Palacio, Sofia
    Akunyili, Ikechukwu Immanuel
    Ernani, Vinicius
    Macintyre, Jessica
    Merchan, Jaime R.
    Pollack, Terri
    Reis, Isildinha
    Restrepo, Maria H.
    Lima, Caio Max S. Rocha
    Hosein, Peter Joel
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] nab-paclitaxel (nab-P) plus nivolumab (Nivo) ± gemcitabine (Gem) in patients (pts) with advanced pancreatic cancer (PC).
    Firdaus, Irfan
    Waterhouse, David Michael
    Gutierrez, Martin
    Wainberg, Zev A.
    George, Ben
    Kelly, Karen
    Bekaii-Saab, Tanios S.
    Carrizosa, Daniel R.
    Soliman, Hatem Hussein
    Fraser, Cindy Duval
    Ko, Amy
    Pierce, Daniel W.
    Manax, Victoria G.
    Stergiopoulos, Sotirios G.
    Hochster, Howard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [10] Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
    Scheithauer, W.
    Von Hoff, D. D.
    Ramanathan, R. K.
    Moore, M.
    Tabernero, J.
    Goldstein, D.
    Hammel, P.
    Kunzmann, V.
    Ko, A.
    Romano, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S614 - S614
12345